A Phase 1/2A Study of the Safety and Efficacy of Modified Stromal Cells (SB623) in Patients With Stable Ischemic Stroke

Trial Profile

A Phase 1/2A Study of the Safety and Efficacy of Modified Stromal Cells (SB623) in Patients With Stable Ischemic Stroke

Completed
Phase of Trial: Phase I/II

Latest Information Update: 23 Dec 2016

At a glance

  • Drugs SB 623 (Primary)
  • Indications Stroke
  • Focus Adverse reactions
  • Sponsors SanBio
  • Most Recent Events

    • 24 Jun 2016 According to SanBio media release, interim (preliminary) results presented of this trial are presented at the International Society of Stem Cell Research Meeting.
    • 02 Jun 2016 According to a SanBio media release, 12-months interim data was published in Stroke, a leading peer-reviewed journal from the American Heart Association.
    • 02 Jun 2016 12-months interim data published in a SanBio media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top